The company has also maintained its financial year 2026 revenue and margin guidance, while remaining mindful of macroeconomic headwinds. Syngene had guided for revenue growth to be in the mid-single-digit range, while margins to moderate from current levels.
Revenue for the quarter increased by 10.7% from last year to ₹874.5 crore, which was higher than estimates of ₹853.1 crore by Kotak.
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at ₹206.4 crore from ₹169.8 crore. The numbers were better than the Kotak estimate of ₹191.9 crore.
EBITDA margin for the quarter expanded by 210 basis points from the year-ago quarter to 23.6%, which was also higher than the 22.5% estimate. However, the margin figure narrowed from the March quarter figure of 33.8%.
Syngene’s revenue and EBITDA are also lower by 14.1% and 40% respectively on a sequential basis.
Net profit for the period increased by 14.5% from last year to ₹83.7 crore. The profit figure for the quarter includes tax benefits from transfer of gratuity funds to Employee Gratuity Trust.
The company said that the growth momentum was driven by conversion of pilot projects to long-term contracts in Research Services business.
Among other key highlights during the quarter:
- Syngene’s Biologics manufacturing unit began operations at Unit III in Bengaluru
- Preparations are also underway to launch Bayview facility in the US later this year
- USFDA’s GCP inspection of Human Pharmacology Unit completed with no observations
- Over 20 client and regulatory audits were successfully completed during the quarter.
Shares of Syngene ended lower after the results announcements during the final minutes of the trading session. The stock ended 1.3% lower at ₹667. The stock is down 25% so far in 2025.
First Published:Â Jul 23, 2025 4:19 PM IST
